Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2

Status

Recruiting 4Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1

Conditions

Breast Neoplasms 1214Neoplasms 1024Carcinoma, Non-Small-Cell Lung 851Prostatic Neoplasms 683Colorectal Neoplasms 608Lung Neoplasms 575Neoplasm Metastasis 431Multiple Myeloma 420Leukemia, Myeloid, Acute 394Pancreatic Neoplasms 371Ovarian Neoplasms 359Melanoma 317Carcinoma, Hepatocellular 284Recurrence 274Squamous Cell Carcinoma of Head and Neck 272Brain Neoplasms 264Glioblastoma 245Head and Neck Neoplasms 241Stomach Neoplasms 236Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Carcinoma, Renal Cell 225Lymphoma 221Triple Negative Breast Neoplasms 216Endometrial Neoplasms 207Hematologic Neoplasms 206Urinary Bladder Neoplasms 195Lymphoma, Non-Hodgkin 194Sarcoma 189Uterine Cervical Neoplasms 187Glioma 187

Interventions

tislelizumab 1fludarabine 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Simpson-Golabi-Behmel syndrome × 90 days × Clear all
NCT06427941 2026-06-03

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

BeOne Medicines

Phase 1 Recruiting
392 enrolled
Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT07513194 2026-04-07

GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)

Baylor College of Medicine

Phase 1 Not yet recruiting
21 enrolled

Simpson-Golabi-Behmel syndrome, Rhabdoid Tumor

NCT06795022 2026-04-06

RHEA-1

AstraZeneca

Phase 1/2 Recruiting
304 enrolled
Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT07500220 2026-03-30

DUET-HCC

Beijing Biotech

Phase 1/2 Recruiting
30 enrolled
Gastrointestinal

Simpson-Golabi-Behmel syndrome, Liver Neoplasms

NCT06687941 2026-03-27

A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

Aptamer Sciences, Inc.

Phase 1 Recruiting
70 enrolled
GastrointestinalThoracic

Simpson-Golabi-Behmel syndrome, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡